Figure 3
From: Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort
Complete response to Pembrolizumab in recurrent metastatic conjunctival melanoma. (a) MRI brain showing a large enhancing mass arising from the left conjunctiva enveloping the left lacrimal gland, at the point of relapse before treatment. (b) Corresponding PET-CT images demonstrating hypermetabolic tumours of the left conjunctiva, left parotid lymph node, (c) abdominal wall as well as erector spinae muscles. (d–f) Complete radiological and metabolic response was achieved after 2 years of Pembrolizumab.
